Brokerages Set UroGen Pharma Ltd. (NASDAQ:URGN) Price Target at $43.70

UroGen Pharma Ltd. (NASDAQ:URGN) has been assigned an average rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $43.70.

URGN has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a report on Tuesday, October 15th. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a research report on Friday, December 6th. Guggenheim initiated coverage on UroGen Pharma in a research report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 target price for the company. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price target on shares of UroGen Pharma in a research report on Wednesday, October 16th. Finally, EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th.

Institutional Trading of UroGen Pharma

Several large investors have recently bought and sold shares of URGN. Vanguard Group Inc. raised its position in shares of UroGen Pharma by 14.3% in the first quarter. Vanguard Group Inc. now owns 194,966 shares of the company’s stock valued at $2,924,000 after buying an additional 24,367 shares during the last quarter. Tidal Investments LLC acquired a new stake in shares of UroGen Pharma during the first quarter worth $425,000. Oak Ridge Investments LLC boosted its holdings in shares of UroGen Pharma by 30.6% during the second quarter. Oak Ridge Investments LLC now owns 79,929 shares of the company’s stock worth $1,341,000 after purchasing an additional 18,725 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of UroGen Pharma by 41.6% in the second quarter. Bank of New York Mellon Corp now owns 96,619 shares of the company’s stock valued at $1,621,000 after purchasing an additional 28,400 shares during the period. Finally, ARK Investment Management LLC increased its stake in UroGen Pharma by 3.7% in the second quarter. ARK Investment Management LLC now owns 151,781 shares of the company’s stock valued at $2,547,000 after purchasing an additional 5,452 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Stock Down 1.1 %

Shares of URGN opened at $12.04 on Friday. The company’s 50-day simple moving average is $12.27 and its 200-day simple moving average is $13.96. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma has a 1 year low of $10.60 and a 1 year high of $20.70. The stock has a market capitalization of $282.34 million, a PE ratio of -3.82 and a beta of 1.06.

UroGen Pharma (NASDAQ:URGN) last released its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same quarter last year, the company earned ($0.68) earnings per share. Analysts forecast that UroGen Pharma will post -3.1 earnings per share for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.